SPACEYour Medical Portal

We’re for those who want the power to extend and more flexibility

Dosing

EYLEA is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) and visual impairment due to diabetic macular oedema (DME).

EYLEA 8mg for your nAMD and DME patients provides you with: 

The power to extend to q12 or q16 directly after only 3 loading doses

q12

Dosing diagram for illustrative purposes only.

After reaching q16, patients can be extended to q20
T&E

Dosing diagram for illustrative purposes only.

Only 3 loading doses, as few as 5 injections in Year 1 and a safety profile consistent with the tried-and-trusted EYLEA 2mg
Explore
Safety
Explore the EYLEA 8mg safety data in nAMD and DME patients
Why a higher dose of EYLEA?
Learn more about the EYLEA Mode of Action
How to inject EYLEA 8mg
Learn the key steps in injecting EYLEA 8mg

  • DME: diabetic macular edema. 

    nAMD: neovascular (wet) age-related macular degeneration. 

    q8: every 8 weeks. 

    q12: every 12 weeks. 

    q16: every 16 weeks. 

    q20: every 20 weeks. 

    T&E: treat and extend.

Next Page
Injection guidance
    • 1
      EYLEA® 8mg (aflibercept 114.3 mg/mL, solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG.
    • 2
      Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-Week results from the Phase 3 PULSAR trial. Retina Society 55th Annual Scientific Meeting. 2–5 November 2022. Pasadena, USA. Oral presentation.
    • 3
      Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. Association for Research in Vision and Ophthalmology 2023 Meeting. 23–27 April 2023. Palo Alto, USA. Oral presentation.
    • a
      Treatment intervals may be further extended up to 5 months, such as with a T&E dosing regimen, while maintaining stable visual and/or anatomic outcomes.¹
    • b
      Patients could receive as few as 5 injections per dosing schedule within the trial protocol.²،³